HDAC1 and colorectal carcinoma: Furthermore, another HDAC1,2,3 inhibitor, valproic acid, was evaluated in a clinical trial in RAS-mutated metastatic CRC patients with the aim of improving the treatment efficacy of standard treatment with the VEGF inhibitor bevacizumab and an oxaliplatin/fluoropyrimidine-based chemotherapy regimen (NCT04310176) [189].